Teva Receives FDA Approval for Biosimilar Version of Amgen's Xgeva
The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries' biosimilar version of Amgen’s Xgeva, known as Degevma. This approval allows Teva to market a more affordable alternative to the original drug used in preventing bone damage and complications in cancer patients. Degevma was granted approval based on analytical data demonstrating its similarity to Xgeva and clinical trials confirming its safety and efficacy. The biosimilar is expected to compete directly with Amgen’s product, potentially impacting pricing dynamics within oncology treatments. This development marks a significant milestone for Teva in expanding its portfolio of biosimilars while offering patients an alternative treatment option.
